ArticleClinical and experimental immunology2000
Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity.
Article in Clinical and experimental immunology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis.Clinics (Sao Paulo, Brazil) · 2020Pooled it
- Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results.Rheumatology international · 2006Trial
- Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis.Clinical and experimental immunology · 2002Trial
- Thrombomodulin Shapes Thrombo-Inflammatory Interactions in Lupus Nephritis.Scandinavian journal of immunology · 2026Article
- Article
- Learning from serum markers reflecting endothelial activation: longitudinal data in childhood-onset systemic lupus erythematosus.Lupus science & medicine · 2024Article
- Dysregulated endothelial cell markers in systemic lupus erythematosus: a systematic review and meta-analysis.Journal of inflammation (London, England) · 2023Review
- Endothelial cell activation and glycocalyx shedding - potential as biomarkers in patients with lupus nephritis.Frontiers in immunology · 2023Review
- Thrombomodulin as a Physiological Modulator of Intravascular Injury.Frontiers in immunology · 2020Review
- Biomarkers associating endothelial Dysregulation in pediatric-onset systemic lupus erythematous.Pediatric rheumatology online journal · 2019Article
- C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation.The FEBS journal · 2019Review
- Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity.Clinical rheumatology · 2018Article
- The Association of Serum Thrombomodulin with Endothelial Injuring Factors in Abdominal Aortic Aneurysm.BioMed research international · 2017Article
- Accelerated recovery from nephrotic syndrome with acute renal failure by double filtration plasmapheresis in a patient with lupus podocytopathy.Clinical and experimental nephrology · 2012Article
- Kinetics of thrombomodulin release and endothelial cell injury by neutrophil-derived proteases and oxygen radicals.Immunology · 2002Article
- Interaction of endothelial cells and neutrophils in vitro: kinetics of thrombomodulin, intercellular adhesion molecule-1 (ICAM-1), E-selectin, and vascular cell adhesion molecule-1 (VCAM-1): implications for the relevance as serological disease activity markers in vasculitides.Clinical and experimental immunology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date no specific serological parameter is available to assess disease activity in SLE. Soluble serum thrombomodulin is a new marker of endothelial cell injury and vasculitis. The objective of this study was to compare in vivo soluble thrombomodulin as marker of disease activity in SLE with established and recent serological parameters. One hundred and twenty-four sera of 30 patients with proven SLE with different disease activities were tested for serum levels of thrombomodulin, intercellular adhesion molecule-1 (ICAM-1), E-selectin, vascular cell adhesion molecule-1 (VCAM-1), IL-2R, IL-6, IL-10, dsDNA by ELISA and dsDNA additionally by radioimmunoassay (RIA). C-reactive protein (CRP), complement component C3, IgG, creatinine, anti-nuclear antibodies (ANA) and intermediate filament antibodies were measured by standard laboratory tests. The clinical disease activity was evaluated by the Systemic Lupus Activity Measure (SLAM). Correlations of the different serological SLE disease activity parameters with the SLAM scores revealed the highest significance for serum thrombomodulin (correlation coefficient 0.82). This was further confirmed by the intra-individual analysis of follow-up sera. In addition, a moderate correlation could be found for IL-6, IL-10, ICAM-1, CRP and erythrocyte sedimentation rate (ESR). In summary, soluble thrombomodulin is the most important serological parameter of disease activity in SLE currently available, as shown by the in vivo studies. Soluble thrombomodulin might be a valuable serological parameter for therapeutical considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.